Tubulis GmbH, the Germany based biotech company developing a new class of highly stable and efficient antibody-drug conjugates (ADCs), has raised EUR 128m in a Series B2 funding round co-led by EQT Life Sciences Group, the Netherlands based independent European investment firm, and Nextech Invest AG, the Switzerland based venture capital and private equity firm, with participation from Frazier Life Sciences, the US based healthcare investment firm, Deep Track Capital, the US based investment firm, Andera Partners, the France based private equity firm, BioMedPartners AG, the Switzerland based venture capital firm, Fund+, the Belgium based venture capital firm, Bayern Kapital GmbH, the Germany based venture capital firm, Evotec AG, the Germany based drug discovery and development company, coparion GmbH & Co. KG, the Germany based venture capital firm, Seventure Partners, the France based venture capital firm, Occident Group AG, the Switzerland and Germany based international venture capital investor, and High-Tech Gründerfonds GmbH, the Germany based seed investor.
- Target – Tubulis GmbH
- Buyer – Occident Group AG
- Buyer – Eqt Life Sciences Group b.v.
- Buyer – Nextech Invest AG
- Buyer – Frazier Life sciences
- Buyer – Deep Track capital
- Buyer – Andera partners
- Buyer – Biomedpartners AG
- Buyer – Fund+
- Buyer – Bayern Kapital GmbH
- Buyer – Evotec se
- Buyer – Coparion Gmbh & Co. kg
- Buyer – Seventure partners
- Buyer – High-tech Gründerfonds Gmbh & Co. kg
- Seller – Shareholders
